Amylin Pharmaceuticals, Inc.'s Sales Force Strategy
|
|
ICMR HOME | Case Studies Collection
To download Amylin Pharmaceuticals, Inc.'s Sales Force Strategy case study
(Case Code: MKTG216) click on the button below, and select the case from the list of available cases:
» Marketing Case Studies
» Marketing Management Short Case Studies
» View Detailed Pricing Info » How To Order This Case
» Business Case Studies
» Case Studies by Area
» Case Studies by Industry
» Case Studies by Company
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
Chat with us
Please leave your feedback
|
Abstract:
The case study is about the sales force strategy of Amylin
Pharmaceuticals, Inc., a San Diego, California-based biopharmaceutical company,
that had developed and marketed two first-in-class drugs for diabetes - Symlin
and Byetta - in the US. The company initially organized its sales force into a
primary care sales force focused on primary care physicians, and a comparatively
smaller specialty sales force focused on endocrinologists and other physicians
with predominant diabetes practices. One of the leading pharmaceutical
companies, Eli Lilly and Company (Lilly), too co-promoted Byetta in the US, and
had its own sales force to promote Byetta. In May 2009, Amylin merged the
primary care and specialty sales force of the company into a single
organization.
|
|
The company hoped that the new sales force strategy with a
leaner sales force would help reduce costs and also increase the effectiveness
of its sales force effort. This decision came at a time when Amylin's board
members were under considerable pressure to step down following the indifferent
performance of the company. The company had come under severe criticism from
activist investors who wanted their own nominees to be incorporated on Amylin's
board. Amylin's sales force strategy was flayed as critics felt that it was
flawed and that it was as a result of this that the company had not been able to
realize the true potential of its first-in-class drugs, particularly Byetta.
Issues:
» To understand the issues and challenges in managing an in-house sales force.
» To understand issues and challenges related to different sales force
organizations, sales force optimization, and sales force productivity.
» To analyze the sales force strategy adopted by Amylin.
» To discuss and debate whether the initial sales force strategy adopted by
Amylin was flawed as claimed by its detractors.
» To analyze the new sales force strategy and discuss whether the new strategy
would help Amylin tap the potential of its products.
» To explore strategies that Amylin could adopt to further improve its sales
force effort.
Contents:
Keywords:
Sales force strategy, Sales organization, Primary care sales
force, specialty sales force, Sales force optimization, Sales force
effectiveness, Sales force productivity, Commercialization, Co-promotion,
Operational costs, SGA expenses, Cash flow, diabetes drug market,
biopharmaceutical, Amylin, Byetta, Eli Lilly
Amylin Pharmaceuticals, Inc.'s Sales Force Strategy
- Next Page>>
|
|